In the Indian pharmaceutical industry, there were 3 private equity deals announced in Q4 2023, worth a total value of $77.3m, according to GlobalData’s Deals Database. The $54.1m investment by Norwest Venture Partners in Regency Healthcare was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.

Smarter leaders trust GlobalData

In value terms, private equity deal activity in India decreased by 73% in Q4 2023 compared with the previous quarter’s total of $281m and fell by 97% as compared to Q4 2022. Related deal volume decreased by 40% in Q4 2023 versus the previous quarter and was 50% lower than in Q4 2022.

The top-ranked financial advisors supporting these private equity deals in India in Q4 2023 were o3 Capital Global Advisory; Veda Corporate Advisors Pvt; Deloitte Touche Tohmatsu with 2, 2, 1 deals respectively.

The top-ranked legal advisorss supporting these private equity deals in India Q4 2023 were Khaitan & Co; Shardul Amarchand Mangaldas & Co; AZB & Partners with 4, 4, 3 deals respectively.

For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in 2023 – Thematic Intelligence, buy the report here.

This content was updated on 8 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.